Healthcare Industry News: neuromodulation
News Release - February 6, 2014
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Independence Blue CrossPositive Coverage Decision Adds 2.2 Million Covered Lives for Up to Two Years of Treatment with Urgent PC
MINNEAPOLIS, Feb. 6, 2014 -- (Healthcare Sales & Marketing Network) -- Uroplasty, Inc. (UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Independence Blue Cross (IBC) has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. IBC covers 2.2 million lives and this decision provides patient coverage for ongoing treatments for up to two years. IBC is the leading health insurer in southeastern Pennsylvania, serving Bucks, Chester, Delaware, Montgomery, and Philadelphia counties.
"This positive coverage decision is another example of the success we are achieving in working directly with payers to demonstrate the cost effectiveness and the clinical benefits of Urgent PC in treating patients with OAB," said Nancy Kolb, Vice President of Healthcare Policy and Reimbursement. "We now have approximately 110 million lives covered by private payers and 40 million Medicare beneficiaries with access to Urgent PC therapy following this decision by IBC."
The policy is available on the Independence BC site at www.ibx.com.
About Overactive Bladder
Overactive bladder (OAB) is a chronic condition that affects approximately 42 million US adults. The symptoms include urinary urgency, frequency and urge incontinence. The Urgent PC neuromodulation System is the only commercially available FDA cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC neuromodulation System, the only commercially available FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.